|Dr. Terrence W. Norchi||Co-Founder, Pres, CEO, Sec. & Director||N/A||N/A||1965|
|Mr. Richard E. Davis||Chief Financial Officer and Treasurer||331.25k||N/A||1958|
|Dr. Avtar S. Dhillon||Bus. Advisor||190k||N/A||1961|
|Mr. Rutledge Ellis-Behnke||Co-Founder & Scientific Advisor||N/A||N/A||N/A|
|Dr. Steven A. Kates Ph.D.||VP of Technology||N/A||N/A||N/A|
Arch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.
Arch Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.